CoQ10 and cognition a review and study protocol for a 90-Day randomized controlled trial investigating the cognitive effects of ubiquinol in the healthy elderly

The purpose of this 2019 trial was to assess the efficacy of CoQ10 (a novel treatment with potential to enhance brain function in healthy elderly populations and known to possess beneficial impacts on oxidative stress, and mitochondrial and vascular function) in ameliorating cognitive decline among a healthy, non-demented sample (aged 60 and over). CoQ10 at a dose of 200mg will be tested against placebo for 90 days in this randomised controlled trial, while cardiovascular function, oxidative stress, liver function and mood will be monitored across 30-, 60- and 90- day time points. Several cognitive determinants were to be used including CogTrack composite measures of cognition (the primary outcome). Stough et al. (2019) regard this trial to be the first of its kind, to provide key clinical and mechanistic data regarding the efficacy of Ubiquinol as a treatment for age-related cognitive impairment in a healthy and elderly population. The trial will provide important implications for productivity and quality of life within this age group. [NPIDs: aging, elderly, cognitive decline, neurodegenerative disorders, dementia, cognition, oxidative stress, mitochondrial, vascular function, liver function, mood, quality of life]

Year: 2019

Reference: Stough, C., Nankivell, M., Camfield, D. A., Perry, N. L., Pipingas, A., Macpherson, H., Wesnes, K., Ou, R., Hare, D., de Haan, J., Head, G., Lansjoen, P., Langsjoen, A., Tan, B., Pase, M. P., King, R., Rowsell, R., Zwalf, O., Rathner, Y., Cooke, M., … Rosenfeldt, F. (2019). CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly. Frontiers in aging neuroscience, 11, 103. https://doi.org/10.3389/fnagi.2019.00103